Literature DB >> 25540139

The organic anion transporter (OAT) family: a systems biology perspective.

Sanjay K Nigam1, Kevin T Bush1, Gleb Martovetsky1, Sun-Young Ahn1, Henry C Liu1, Erin Richard1, Vibha Bhatnagar1, Wei Wu1.   

Abstract

The organic anion transporter (OAT) subfamily, which constitutes roughly half of the SLC22 (solute carrier 22) transporter family, has received a great deal of attention because of its role in handling of common drugs (antibiotics, antivirals, diuretics, nonsteroidal anti-inflammatory drugs), toxins (mercury, aristolochic acid), and nutrients (vitamins, flavonoids). Oats are expressed in many tissues, including kidney, liver, choroid plexus, olfactory mucosa, brain, retina, and placenta. Recent metabolomics and microarray data from Oat1 [Slc22a6, originally identified as NKT (novel kidney transporter)] and Oat3 (Slc22a8) knockouts, as well as systems biology studies, indicate that this pathway plays a central role in the metabolism and handling of gut microbiome metabolites as well as putative uremic toxins of kidney disease. Nuclear receptors and other transcription factors, such as Hnf4α and Hnf1α, appear to regulate the expression of certain Oats in conjunction with phase I and phase II drug metabolizing enzymes. Some Oats have a strong selectivity for particular signaling molecules, including cyclic nucleotides, conjugated sex steroids, odorants, uric acid, and prostaglandins and/or their metabolites. According to the "Remote Sensing and Signaling Hypothesis," which is elaborated in detail here, Oats may function in remote interorgan communication by regulating levels of signaling molecules and key metabolites in tissues and body fluids. Oats may also play a major role in interorganismal communication (via movement of small molecules across the intestine, placental barrier, into breast milk, and volatile odorants into the urine). The role of various Oat isoforms in systems physiology appears quite complex, and their ramifications are discussed in the context of remote sensing and signaling.
Copyright © 2015 the American Physiological Society.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25540139      PMCID: PMC4281586          DOI: 10.1152/physrev.00025.2013

Source DB:  PubMed          Journal:  Physiol Rev        ISSN: 0031-9333            Impact factor:   37.312


  299 in total

1.  Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes.

Authors:  N Apiwattanakul; T Sekine; A Chairoungdua; Y Kanai; N Nakajima; S Sophasan; H Endou
Journal:  Mol Pharmacol       Date:  1999-05       Impact factor: 4.436

Review 2.  Developmental pharmacokinetics.

Authors:  Gail D Anderson
Journal:  Semin Pediatr Neurol       Date:  2010-12       Impact factor: 1.636

Review 3.  Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles.

Authors:  Ahsan N Rizwan; Gerhard Burckhardt
Journal:  Pharm Res       Date:  2007-03       Impact factor: 4.200

Review 4.  Real and artificial immune systems: computing the state of the body.

Authors:  Irun R Cohen
Journal:  Nat Rev Immunol       Date:  2007-07       Impact factor: 53.106

5.  Development of mechanisms for drug excretion.

Authors:  J B Hook; W R Hewitt
Journal:  Am J Med       Date:  1977-04       Impact factor: 4.965

6.  A novel putative transporter maps to the osteosclerosis (oc) mutation and is not expressed in the oc mutant mouse.

Authors:  K P Brady; H Dushkin; D Förnzler; T Koike; F Magner; H Her; S Gullans; G V Segre; R M Green; D R Beier
Journal:  Genomics       Date:  1999-03-15       Impact factor: 5.736

7.  A three-dimensional model of human organic anion transporter 1: aromatic amino acids required for substrate transport.

Authors:  Jennifer L Perry; Neetu Dembla-Rajpal; Laura A Hall; John B Pritchard
Journal:  J Biol Chem       Date:  2006-10-11       Impact factor: 5.157

Review 8.  Organic anion transporters and their implications in pharmacotherapy.

Authors:  Arian Emami Riedmaier; Anne T Nies; Elke Schaeffeler; Matthias Schwab
Journal:  Pharmacol Rev       Date:  2012-03-28       Impact factor: 25.468

9.  Functional and immunochemical characterization of a novel organic anion transporter Oat8 (Slc22a9) in rat renal collecting duct.

Authors:  Hirokazu Yokoyama; Naohiko Anzai; Marija Ljubojevic; Naoko Ohtsu; Takeshi Sakata; Hiroki Miyazaki; Hiroshi Nonoguchi; Rafiqul Islam; Maristella Onozato; Akihiro Tojo; Kimio Tomita; Yoshikatsu Kanai; Takashi Igarashi; Ivan Sabolic; Hitoshi Endou
Journal:  Cell Physiol Biochem       Date:  2008-04-23

Review 10.  Metabolomics in chronic kidney disease.

Authors:  Ying-Yong Zhao
Journal:  Clin Chim Acta       Date:  2013-04-06       Impact factor: 3.786

View more
  134 in total

1.  Perfluorinated Chemicals as Emerging Environmental Threats to Kidney Health: A Scoping Review.

Authors:  John W Stanifer; Heather M Stapleton; Tomokazu Souma; Ashley Wittmer; Xinlu Zhao; L Ebony Boulware
Journal:  Clin J Am Soc Nephrol       Date:  2018-09-13       Impact factor: 8.237

2.  Indoxyl sulfate associates with cardiovascular phenotype in children with chronic kidney disease.

Authors:  Johannes Holle; Uwe Querfeld; Marietta Kirchner; Alexandros Anninos; Jürgen Okun; Daniela Thurn-Valsassina; Aysun Bayazit; Ana Niemirska; Nur Canpolat; Ipek Kaplan Bulut; Ali Duzova; Ali Anarat; Rukshana Shroff; Yelda Bilginer; Salim Caliskan; Cengiz Candan; Jerome Harambat; Zeynep Birsin Özcakar; Oguz Soylemezoglu; Sibylle Tschumi; Sandra Habbig; Ebru Yilmaz; Ayse Balat; Aleksandra Zurowska; Nilgun Cakar; Birgitta Kranz; Pelin Ertan; Anette Melk; Karolis Azukaitis; Franz Schaefer
Journal:  Pediatr Nephrol       Date:  2019-08-19       Impact factor: 3.714

Review 3.  The SLC22 Transporter Family: A Paradigm for the Impact of Drug Transporters on Metabolic Pathways, Signaling, and Disease.

Authors:  Sanjay K Nigam
Journal:  Annu Rev Pharmacol Toxicol       Date:  2018-01-06       Impact factor: 13.820

Review 4.  Drug Transporters and Na+/H+ Exchange Regulatory Factor PSD-95/Drosophila Discs Large/ZO-1 Proteins.

Authors:  Dustin R Walsh; Thomas D Nolin; Peter A Friedman
Journal:  Pharmacol Rev       Date:  2015-07       Impact factor: 25.468

Review 5.  Medications in Space: In Search of a Pharmacologist's Guide to the Galaxy.

Authors:  Sara Eyal; Hartmut Derendorf
Journal:  Pharm Res       Date:  2019-08-14       Impact factor: 4.200

6.  Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk: 2021 update.

Authors:  Claudio Borghi; Justyna Domienik-Karłowicz; Andrzej Tykarski; Krystyna Widecka; Krzysztof J Filipiak; Miłosz J Jaguszewski; Krzysztof Narkiewicz; Giuseppe Mancia
Journal:  Cardiol J       Date:  2021-01-13       Impact factor: 2.737

Review 7.  Choroid Plexus and Drug Removal Mechanisms.

Authors:  Austin Sun; Joanne Wang
Journal:  AAPS J       Date:  2021-05-03       Impact factor: 4.009

Review 8.  Trafficking and other regulatory mechanisms for organic anion transporting polypeptides and organic anion transporters that modulate cellular drug and xenobiotic influx and that are dysregulated in disease.

Authors:  Michael Murray; Fanfan Zhou
Journal:  Br J Pharmacol       Date:  2017-04-24       Impact factor: 8.739

Review 9.  Cell-surface G-protein-coupled receptors for tumor-associated metabolites: A direct link to mitochondrial dysfunction in cancer.

Authors:  Bojana Ristic; Yangzom D Bhutia; Vadivel Ganapathy
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-05-13       Impact factor: 10.680

10.  Compensatory Renal Hypertrophy and the Uptake of Cysteine S-Conjugates of Hg2+ in Isolated S2 Proximal Tubular Segments.

Authors:  Christy C Bridges; Delon W Barfuss; Lucy Joshee; Rudolfs K Zalups
Journal:  Toxicol Sci       Date:  2016-08-25       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.